Medpace Holdings, Inc.

Good day, ladies and gentlemen, and welcome to the MedPay second quarter 2021 earnings conference call. At this time, all participants are in a listen-only mode. Later, we will conduct question-and-answer session, and instruction will follow at that time. If anyone should require operator assistance, please press star, then zero on your touchstone telephone. As a reminder, this call may be recorded. I would now like to introduce your host for today's conference call, Lauren Morris, MedPace Associate Director of Investors Relations. Lauren, you may begin.

Good morning, and thank you for joining MedPace's second quarter 2021 earnings conference call. Also on the call today is our President and CEO, August Trundle, our CFO and COO of Laboratory Operations, Jesse Geiger, and our Executive Director of Finance, Kevin Brady. Before we begin, I would like to remind you that our remarks and responses to your questions during this teleconference may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve inherent assumptions with known and unknown risks and uncertainties, as well as other important factors that could cause actual results to differ materially from our current expectations. These factors, including the ongoing impact of COVID-19 on our business are discussed in our Form 10-K and other filings with the SEC. Please note that we assume no obligation to update forward-looking statements, even if estimates change. Accordingly, you should not rely on any of today's forward-looking statements as representing our views as of any date after today. During this call, we will also be referring to certain non-GAAP financial measures. These non-GAAP measures are not superior to or a replacement for the comparable GAAP measures but we believe these measures help investors gain a more complete understanding of results. A reconciliation of such non-GAAP financial measures to the most directly comparable GAAP measures is available in our earnings press release and earnings call presentation slides provided in connection with today's call. The slides are available in the investor relations section of our website at investor.medpace.com. With that, I would now like to turn the call over to August Trundle.

Thank you, Lauren. Good morning, everyone. In a press release issued yesterday, we announced several changes to our senior management team. Effective August 1st, Jesse Geiger will be elevated to the position of president, and Kevin Brady will succeed Jesse as chief financial officer. I will continue to serve as chairman of the board and chief executive officer. Jesse has served as our chief financial officer since 2011, and he expanded that role in 2014 to include the title of Chief Operating Officer of Laboratory Operations. Jesse has played key roles during our rapid growth in the past decade, and we are fortunate to have his leadership to drive our growth going forward. Oversight of the operating activities of the company will increasingly be a shared responsibility of Jesse and myself. Kevin has served as our Executive Director of Finance and Treasurer since joining MetBase in 2018. with oversight of the company's finance function. We are confident that Kevin's current and previous experience in public company finance will serve MedBase well in his new role. And now, I'd like to turn the call over to Jesse.